234 related articles for article (PubMed ID: 34573231)
1. The Effect of Cannabis-Based Medicine on Neuropathic Pain and Spasticity in Patients with Multiple Sclerosis and Spinal Cord Injury: Study Protocol of a National Multicenter Double-Blinded, Placebo-Controlled Trial.
Hansen JS; Hansen RM; Petersen T; Gustavsen S; Oturai AB; Sellebjerg F; Sædder EA; Kasch H; Rasmussen PV; Finnerup NB; Svendsen KB
Brain Sci; 2021 Sep; 11(9):. PubMed ID: 34573231
[TBL] [Abstract][Full Text] [Related]
2. Cannabis-Based Medicine for Neuropathic Pain and Spasticity-A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial.
Hansen JS; Gustavsen S; Roshanisefat H; Kant M; Biering-Sørensen F; Andersen C; Olsson A; Chow HH; Asgari N; Hansen JR; Nielsen HH; Hansen RM; Petersen T; Oturai AB; Sellebjerg F; Sædder EA; Kasch H; Rasmussen PV; Finnerup NB; Svendsen KB
Pharmaceuticals (Basel); 2023 Jul; 16(8):. PubMed ID: 37630995
[TBL] [Abstract][Full Text] [Related]
3. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of cannabis-based medicine in a patient population included in a randomized, placebo-controlled, clinical trial.
Hansen JS; Boix F; Hasselstrøm JB; Sørensen LK; Kjolby M; Gustavsen S; Hansen RM; Petersen T; Sellebjerg F; Kasch H; Rasmussen PV; Finnerup NB; Saedder EA; Svendsen KB
Clin Transl Sci; 2024 Jan; 17(1):e13685. PubMed ID: 38054364
[TBL] [Abstract][Full Text] [Related]
5. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.
Rog DJ; Nurmikko TJ; Friede T; Young CA
Neurology; 2005 Sep; 65(6):812-9. PubMed ID: 16186518
[TBL] [Abstract][Full Text] [Related]
6. A Critical Review of the Role of the Cannabinoid Compounds Δ
Jones É; Vlachou S
Molecules; 2020 Oct; 25(21):. PubMed ID: 33113776
[TBL] [Abstract][Full Text] [Related]
7. Sativex
Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
[TBL] [Abstract][Full Text] [Related]
8. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
Collin C; Davies P; Mutiboko IK; Ratcliffe S;
Eur J Neurol; 2007 Mar; 14(3):290-6. PubMed ID: 17355549
[TBL] [Abstract][Full Text] [Related]
10. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
11. A randomised controlled cross-over double-blind pilot study protocol on THC:CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity.
Marinelli L; Balestrino M; Mori L; Puce L; Rosa GM; Giorello L; Currà A; Fattapposta F; Serrati C; Gandolfo C; Abbruzzese G; Trompetto C
BMJ Open; 2017 Sep; 7(9):e016843. PubMed ID: 28882919
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
[TBL] [Abstract][Full Text] [Related]
13. Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment.
Zubcevic K; Petersen M; Bach FW; Heinesen A; Enggaard TP; Almdal TP; Holbech JV; Vase L; Jensen TS; Hansen CS; Finnerup NB; Sindrup SH
Eur J Pain; 2023 Apr; 27(4):492-506. PubMed ID: 36571471
[TBL] [Abstract][Full Text] [Related]
14. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
15. A selective review of medical cannabis in cancer pain management.
Blake A; Wan BA; Malek L; DeAngelis C; Diaz P; Lao N; Chow E; O'Hearn S
Ann Palliat Med; 2017 Dec; 6(Suppl 2):S215-S222. PubMed ID: 28866904
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.
Vaney C; Heinzel-Gutenbrunner M; Jobin P; Tschopp F; Gattlen B; Hagen U; Schnelle M; Reif M
Mult Scler; 2004 Aug; 10(4):417-24. PubMed ID: 15327040
[TBL] [Abstract][Full Text] [Related]
17. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.
Wade DT; Robson P; House H; Makela P; Aram J
Clin Rehabil; 2003 Feb; 17(1):21-9. PubMed ID: 12617376
[TBL] [Abstract][Full Text] [Related]
18. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain.
Johnson JR; Burnell-Nugent M; Lossignol D; Ganae-Motan ED; Potts R; Fallon MT
J Pain Symptom Manage; 2010 Feb; 39(2):167-79. PubMed ID: 19896326
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
Rice J; Cameron M
Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
[TBL] [Abstract][Full Text] [Related]
20. Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.
Liu Z; Galettis P; Broyd SJ; van Hell H; Greenwood LM; de Krey P; Steigler A; Zhu X; Schneider J; Solowij N; Martin JH
Intern Med J; 2020 Jul; 50(7):846-853. PubMed ID: 31264294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
